Dynatronics Corporation (DYNT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Dynatronics Corporation (DYNT) trades at $0.04 with AI Score 39/100 (Grade D). Dynatronics Corporation designs, manufactures, and distributes medical devices for physical therapy, rehabilitation, orthopedics, pain management, and athletic training across the U. Market cap: $403,612, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for DYNT: DYNT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DYNT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DYNT: 1/1 perspectives are bearish.
How is this calculated? →Dynatronics Corporation (DYNT) Healthcare & Pipeline Overview
Dynatronics Corporation is a medical device manufacturer and distributor specializing in physical therapy, rehabilitation, orthopedics, and pain management products for U.S. and international markets. The company provides a comprehensive range of orthopedic bracing, therapeutic modalities, and clinical equipment, serving healthcare professionals and institutions with established brands.
What Is the Investment Thesis for DYNT?
Dynatronics Corporation operates within the growing medical device sector, specifically targeting physical therapy, rehabilitation, and pain management markets. The company's broad product portfolio, encompassing orthopedic bracing, advanced therapeutic modalities, and clinical equipment, positions it to capitalize on increasing demand for non-invasive treatment solutions driven by an aging population and rising prevalence of chronic conditions. With a gross margin of 21.5%, the company demonstrates some efficiency in its manufacturing and distribution. However, a negative profit margin of -40.0% indicates significant operational challenges or investment phases that require close monitoring. The company's established brands like Bird & Cronin and Hausmann, coupled with its direct sales and online platform, provide a foundation for market penetration. Future growth catalysts could include expansion into new therapeutic applications for its modality devices, strategic partnerships to enhance distribution, or product innovation in areas like connected health for rehabilitation. As an OTC Other listed company, investors face higher liquidity and disclosure risks, necessitating thorough due diligence into its financial health and compliance. The company's current market capitalization is $0.00B, reflecting its small scale and the inherent volatility associated with micro-cap stocks.
Based on FMP financials and quantitative analysis
DYNT Key Highlights
- Gross Margin: Dynatronics reported a gross margin of 21.5%, indicating the profitability of its core product sales before operating expenses.
- Profit Margin: The company currently has a profit margin of -40.0%, reflecting significant losses relative to its revenue, which suggests operational inefficiencies or substantial investments.
- Market Capitalization: Dynatronics has a market capitalization of 404K, positioning it as a micro-cap company with potentially higher volatility and lower liquidity.
- Beta: With a Beta of 0.31, Dynatronics' stock price has historically been less volatile than the overall market, suggesting a relatively stable price movement compared to broader market fluctuations.
- Dividend Policy: The company does not currently offer a dividend, indicating a strategy of reinvesting earnings back into the business or reflecting its current unprofitability.
Who Are DYNT's Competitors?
DYNT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DYNT's Key Strengths?
- Diverse product portfolio covering multiple therapeutic areas (physical therapy, orthopedics, pain management).
- Established brand recognition with names like Bird & Cronin and Hausmann.
- Direct sales and online distribution channels reaching a broad professional clientele.
- International export presence in approximately 30 countries.
What Are DYNT's Weaknesses?
- Negative profit margin of -40.0% indicates significant unprofitability.
- Small market capitalization ($0.00B) suggests limited financial resources and market influence.
- OTC Other listing implies higher risk, lower liquidity, and potentially less regulatory oversight.
- Reliance on the highly regulated and competitive medical device industry.
What Could Drive DYNT Stock Higher?
- Potential for new product launches in advanced therapeutic modalities or orthopedic bracing to address evolving market needs.
- Strategic partnerships or distribution agreements that could expand market reach or enhance product offerings, particularly in international markets.
- Any improvements in financial performance, such as a reduction in the negative profit margin or growth in gross margin, signaling operational efficiencies.
- Continuous demand for physical therapy and rehabilitation products driven by an aging population and increasing prevalence of chronic conditions.
- Efforts to enhance compliance and disclosure, potentially leading to an uplisting within the OTC tiers and improved investor confidence.
What Are the Key Risks for DYNT?
- Financial-distress signal — its Altman Z-Score of -4.23 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant unprofitability, as evidenced by a -40.0% profit margin, which raises concerns about long-term financial viability without substantial operational improvements.
- High competition within the medical device industry from larger, better-resourced companies that could out-innovate or out-market Dynatronics.
- Regulatory changes or increased scrutiny in the medical device sector, potentially leading to higher compliance costs or restrictions on product sales.
- Limited liquidity and transparency associated with its "OTC Other" listing, posing challenges for investors in terms of trading and access to information.
- Economic downturns or shifts in healthcare spending policies that could reduce demand for elective rehabilitation services or impact hospital budgets for equipment purchases.
What Are the Growth Opportunities for DYNT?
- Expansion in Non-Invasive Pain Management Solutions: The global market for non-invasive pain management is experiencing robust growth, driven by increasing awareness of opioid risks and a preference for alternative therapies. Dynatronics, with its electrotherapy, ultrasound, phototherapy, and therapeutic laser devices, is well-positioned to capitalize on this trend. Expanding its R&D into next-generation non-pharmacological pain relief technologies and securing broader clinical adoption could significantly increase market share. This market is projected to grow at a CAGR of over 7% through 2030, offering substantial long-term revenue potential for specialized device manufacturers.
- Increased Demand from Aging Population and Chronic Conditions: The demographic shift towards an older population globally, coupled with the rising incidence of chronic conditions like arthritis, diabetes-related complications, and neurological disorders, fuels a continuous demand for rehabilitation and physical therapy products. Dynatronics' extensive range of orthopedic bracing, clinical equipment, and therapeutic modalities directly addresses these needs. By enhancing its product lines to cater specifically to geriatric care and long-term rehabilitation, the company can tap into a consistently expanding market segment, ensuring sustained demand over the next decade.
- Growth in Sports Medicine and Athletic Training: The increasing participation in sports and physical activities, alongside a greater focus on injury prevention and rapid recovery among athletes, drives demand for specialized sports medicine and athletic training products. Dynatronics' offerings, including cold therapy items, bracing solutions, and various exercise equipment, are directly relevant to this market. Strategic partnerships with sports organizations, athletic training facilities, and professional teams, coupled with targeted product development for athletic performance and recovery, could unlock significant growth within this segment over the next 5-7 years.
- Geographic Expansion in International Markets: While Dynatronics currently exports to approximately 30 international locations, there remains substantial untapped potential in emerging markets and regions with developing healthcare infrastructures. Many countries are investing in modernizing their healthcare systems, including rehabilitation services. By strategically identifying and entering new international markets with high growth potential for medical devices, possibly through local partnerships or direct sales expansion, Dynatronics could diversify its revenue streams and reduce reliance on the U.S. market, targeting growth over the next 5-10 years.
- Product Innovation in Connected Health and Digital Rehabilitation: The integration of technology, such as IoT and AI, into medical devices for remote monitoring, personalized therapy, and data-driven insights, represents a significant growth frontier. Dynatronics could develop smart versions of its therapeutic modalities or incorporate digital platforms for rehabilitation exercises and progress tracking. This innovation would allow for enhanced patient engagement, improved outcomes, and new revenue models (e.g., subscription services for digital platforms), appealing to a tech-savvy healthcare market over the next 3-5 years.
What Opportunities Does DYNT Have?
- Growing demand for non-invasive pain management solutions.
- Increasing needs from an aging population requiring rehabilitation and physical therapy.
- Expansion into new geographic markets or deeper penetration in existing international markets.
- Potential for product innovation in connected health or digital rehabilitation technologies.
What Threats Does DYNT Face?
- Intense competition from larger, well-capitalized medical device manufacturers.
- Regulatory changes and compliance costs in the medical device sector.
- Economic downturns impacting healthcare spending by clinics and hospitals.
- Supply chain disruptions affecting manufacturing and distribution.
What Are DYNT's Competitive Advantages?
- Established Brand Portfolio: Owns and markets products under recognized brands like Bird & Cronin, Solaris, and Hausmann, which have built trust and reputation in the medical community over time.
- Comprehensive Product Range: Offers a wide and integrated suite of products covering multiple aspects of physical therapy, rehabilitation, and orthopedics, providing a one-stop solution for many practitioners.
- Specialized Expertise: Possesses deep knowledge and experience in the niche markets of physical therapy and rehabilitation medical devices, allowing for targeted product development and customer service.
- Direct Sales and Distribution Network: Maintains a direct sales force and online platform, potentially fostering stronger customer relationships and efficient market reach compared to relying solely on third-party distributors.
What Does DYNT Do?
Dynatronics Corporation, founded in 1979 and headquartered in Eagan, Minnesota, operates as a dedicated medical device firm. The company's core business involves the creation, production, and distribution of essential products tailored for physical therapy, rehabilitation, orthopedics, pain management, and athletic training. While its primary operational footprint is within the United States, Dynatronics also extends its market reach by exporting its goods to approximately 30 international locations, demonstrating a global presence in specialized medical device markets. The company's extensive product portfolio is a key differentiator, encompassing a wide array of orthopedic soft bracing solutions. These include critical items such as cervical collars, shoulder immobilizers, arm slings, various supports for wrists, elbows, abdominals, and lumbosacral regions, as well as maternity supports, knee immobilizers, ankle walkers, plantar fasciitis splints, and cold therapy items designed to aid recovery and support. Beyond bracing, Dynatronics provides advanced therapeutic modality devices, which are crucial for modern clinical practices. This category features sophisticated systems for electrotherapy, ultrasound, phototherapy, therapeutic lasers, shortwave diathermy, radial pulse therapy, hot and cold treatment, and compression therapy, alongside essential electrodes. For equipping clinical environments, their offerings are comprehensive, ranging from powered and manually operated treatment tables, mat platforms, and specialized work tables to parallel bars, training stairs, weight racks, treadmills, and other associated exercise equipment vital for rehabilitation. Furthermore, the company supplies crucial clinical consumables, including exercise bands and tubing, lotions and gels, additional orthopedic bracings, paper products, and sundry related supplies, ensuring a complete solution for practitioners. These varied products are marketed under well-established brands such as Bird & Cronin, Solaris, Hausmann, Physician's Choice, and PROTEAM, which resonate with professional users. Dynatronics serves a broad professional clientele, including orthopedists, physical therapists, chiropractors, athletic trainers, and sports medicine practitioners, in addition to larger institutions like clinics and hospitals, leveraging both direct sales channels and an online platform for distribution efficiency.
What Products and Services Does DYNT Offer?
- Designs and manufactures medical devices for physical therapy, rehabilitation, orthopedics, pain management, and athletic training.
- Produces a wide range of orthopedic soft bracing solutions, including collars, immobilizers, slings, and various supports.
- Develops advanced therapeutic modality devices such as electrotherapy, ultrasound, phototherapy, and laser systems.
- Supplies clinical equipment for rehabilitation centers, including treatment tables, parallel bars, training stairs, and treadmills.
- Offers essential clinical consumables like exercise bands, lotions, gels, and paper products.
- Distributes products under established brands such as Bird & Cronin, Solaris, Hausmann, Physician's Choice, and PROTEAM.
- Serves a diverse professional clientele including orthopedists, physical therapists, chiropractors, and hospitals.
- Operates primarily in the United States, with exports to approximately 30 international countries.
How Does DYNT Make Money?
- Product Sales: Generates revenue through the direct sale of its manufactured medical devices and consumables to healthcare professionals and institutions.
- Brand Leverage: Utilizes established brand names like Bird & Cronin and Hausmann to build trust and market share within specialized medical fields.
- Multi-Channel Distribution: Employs both a direct sales force and an online platform to reach its diverse customer base efficiently.
- International Exports: Expands revenue opportunities by exporting products to approximately 30 international markets, diversifying its geographic sales.
What Industry Does DYNT Operate In?
Dynatronics Corporation operates within the dynamic Healthcare sector, specifically in the Medical Devices industry, focusing on physical therapy, rehabilitation, orthopedics, and pain management. This industry segment is characterized by steady growth, primarily driven by an aging global population, increasing prevalence of chronic diseases, and a rising emphasis on non-invasive treatment and preventative care. The global physical therapy equipment market, for instance, is projected to expand significantly, fueled by sports injuries, neurological disorders, and post-operative rehabilitation needs. Dynatronics positions itself by offering a comprehensive suite of products, from orthopedic bracing to advanced therapeutic modalities and clinical equipment, under established brands. The competitive landscape includes both larger, diversified medical device manufacturers and smaller, specialized players. Dynatronics differentiates through its broad product range and established distribution channels serving a professional clientele. Its ability to innovate and adapt to evolving healthcare demands, especially in non-invasive pain management, will be critical for maintaining and expanding its market share within this competitive and regulated environment.
Who Are DYNT's Key Customers?
- Orthopedists and orthopedic clinics
- Physical therapists and rehabilitation centers
- Chiropractors
- Athletic trainers and sports medicine practitioners
- Hospitals and larger healthcare institutions
Key Financial Metrics
Return on assets is -71.6%, showing how much profit it generates from its asset base. A current ratio of 1.07 indicates the company holds enough short-term assets to cover its near-term obligations.
Dynatronics Corporation (DYNT) Valuation Context
Valued at 404K, DYNT is classified as a micro-cap stock. Relative to its peer group, DYNT's quantitative score of 39/100 is below the peer average of 69/100.
Company Profile
Dynatronics Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Eagan, US. The company is led by CEO Brian D. Baker. DYNT has traded publicly since 1983.
F-Score 3/9Financial Health
Dynatronics Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.23 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Dynatronics Corporation revenue of about $54.4M for fiscal 2026, with EPS near $0.90.
DYNT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in upcoming growth.
- Community sentiment has shifted positively, with discussions highlighting recent product innovations that could drive sales.
- The company's focus on expanding its market presence has garnered attention, with many investors optimistic about its strategic direction.
- Recent partnerships in the healthcare sector have sparked interest, as they could lead to increased distribution and revenue opportunities.
Bear Case
- Concerns over operational efficiency have been raised, with some analysts questioning the company's ability to manage costs effectively.
- Social sentiment has shown skepticism, particularly regarding the competitive landscape and how Dynatronics can maintain its market share.
- Recent earnings reports were mixed, leading to doubts about the company's short-term performance and growth trajectory.
- Some community members express caution, citing potential regulatory challenges that could impact future operations and profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
DYNT Latest News
No recent news available for DYNT.
DYNT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DYNT.
Price Targets
Wall Street price target analysis for DYNT.
DYNT MoonshotScore
What does this score mean?
The MoonshotScore rates DYNT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Brian D. Baker
Chief Executive Officer
Brian D. Baker serves as the Chief Executive Officer of Dynatronics Corporation, overseeing the strategic direction and operational management of the medical device company. While specific details regarding his prior career history, educational background, or previous roles before Dynatronics are not provided in the source data, his leadership is central to the company's operations, which includes managing its 111 employees. His role involves navigating the complexities of the medical device industry, from product development and manufacturing to sales and international distribution, across various therapeutic areas.
Track Record: Under Brian D. Baker's leadership, Dynatronics Corporation continues its mission to design, manufacture, and distribute essential products for physical therapy, rehabilitation, orthopedics, and pain management. His tenure has seen the company maintain its diverse product range under established brands such as Bird & Cronin and Hausmann, serving a broad professional clientele. He is responsible for guiding the company's efforts in both its primary U.S. market and its export activities to approximately 30 international locations, ensuring operational continuity and strategic alignment in a competitive healthcare landscape.
DYNT OTC Market Information
Dynatronics Corporation trades on the OTC market under the "OTC Other" tier. This classification signifies that the company does not meet the minimum disclosure requirements for OTCQX or OTCQB, nor does it qualify for the Pink Open Market. Companies in the OTC Other tier typically have limited public information available, which can include a lack of current financial reports or audited statements. This contrasts significantly with exchanges like NYSE or NASDAQ, which impose stringent listing standards regarding financial health, corporate governance, and minimum share price, ensuring a higher level of transparency and investor protection.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and wide bid-ask spreads, making it difficult to trade shares.
- Potentially insufficient or inconsistent public financial disclosures due to "Unknown" disclosure status.
- Higher susceptibility to market manipulation due to lower trading volumes and less regulatory oversight.
- Difficulty in obtaining reliable valuation metrics and analyst coverage.
- Increased risk of delisting or further restrictions if compliance with OTC requirements is not met.
- Verify the availability and recency of financial statements and annual reports directly from the company or OTC Markets.
- Research any news or press releases regarding regulatory compliance or corporate actions.
- Assess the company's operational viability and competitive position within its specific medical device niche.
- Examine management's background and track record beyond what is publicly available.
- Understand the company's capital structure, debt levels, and cash flow generation.
- Evaluate the transparency of corporate governance practices.
- Consider the potential for future uplisting to a higher OTC tier or national exchange.
- Established operating history since 1979, indicating long-term business continuity.
- Physical headquarters in Eagan, US, suggesting a tangible operational base.
- Clear business description involving manufacturing and distribution of medical devices.
- Named CEO, Brian D. Baker, and a stated employee count of 111, indicating an active management team and workforce.
- Owns and markets products under established brands like Bird & Cronin and Hausmann.
What Investors Ask About Dynatronics Corporation (DYNT) — Healthcare
What products and services does Dynatronics Corporation offer in the healthcare market?
Dynatronics Corporation specializes in a comprehensive range of medical devices and related products for physical therapy, rehabilitation, orthopedics, pain management, and athletic training. Its offerings include an extensive selection of orthopedic soft bracing solutions such as cervical collars, shoulder immobilizers, and various supports for different body parts, alongside cold therapy items. The company also provides advanced therapeutic modality devices, encompassing systems for electrotherapy, ultrasound, phototherapy, therapeutic lasers, and compression therapy. For clinical environments, Dynatronics supplies a variety of treatment tables, exercise equipment, and essential clinical consumables like exercise bands, lotions, and paper products. These products are sold under established brands like Bird & Cronin, Solaris, and Hausmann, serving a broad professional clientele.
Given its OTC Other listing, what are the primary concerns for investors regarding Dynatronics Corporation's transparency and liquidity?
As an OTC Other listed company, Dynatronics Corporation presents specific transparency and liquidity concerns for investors. The "OTC Other" tier indicates that the company may not meet the stringent disclosure requirements of higher exchanges or even other OTC tiers, and its disclosure status is "Unknown." This can mean limited public access to current financial reports or audited statements, making comprehensive due diligence challenging. Furthermore, a market capitalization of 404K and an OTC Other listing often correlate with significantly lower trading volumes and wider bid-ask spreads. This reduced liquidity can make it difficult for investors to buy or sell shares efficiently at desired prices, potentially leading to increased price volatility and difficulty in exiting positions.
What are the key growth opportunities for Dynatronics Corporation within the evolving healthcare landscape?
Dynatronics Corporation has several key growth opportunities within the evolving healthcare landscape. One significant area is the increasing demand for non-invasive pain management solutions, where its electrotherapy, ultrasound, and therapeutic laser devices can capitalize on the shift away from opioid reliance. The global aging population and the rising prevalence of chronic conditions also drive a continuous need for rehabilitation and physical therapy products, directly aligning with Dynatronics' core offerings in orthopedic bracing and clinical equipment. Furthermore, the burgeoning sports medicine market, focused on injury prevention and recovery, presents an opportunity for specialized product development. Lastly, potential geographic expansion into underserved international markets and innovation in connected health technologies for digital rehabilitation could unlock new revenue streams and enhance market positioning.
What are the key factors to evaluate for DYNT?
Dynatronics Corporation (DYNT) holds an AI score of 39/100 (low). Not financial advice.
How frequently does DYNT data refresh on this page?
DYNT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DYNT's recent stock price performance?
Dynatronics Corporation (DYNT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio covering multiple therapeutic areas (physical therapy, orthopedics, pain management). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DYNT overvalued or undervalued right now?
Valuing Dynatronics Corporation (DYNT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DYNT?
Before investing in Dynatronics Corporation (DYNT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- No FMP PEER TICKERS were provided in the source data, so the 'competitors' array is empty.
- CEO tenureYears not provided.
- Analyst consensus data not provided, so the corresponding FAQ was omitted and replaced with a company-fundamentals FAQ.
- Market Cap is $0.00B, which is an unusual value and might indicate a very small or unrecorded market cap. Using the provided value as-is.